Benzinga
10 Aug 2026, 18:02 UTC · 14h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Sionna Therapeutics has discontinued the development of its cystic fibrosis drug candidate SION-719 after it missed its primary activity target in a Phase 2a trial. — The failure of a primary clinical trial candidate typically leads to massive loss of company valuation, as evidenced by the stock's 91.84% drop.
-1.00A Phase 1 study of SION-451 in combination with SION-2222 or SION-109 met its target safety, tolerability, and pharmacokinetic objectives. — Positive early-stage data provides a small hedge against the total collapse of the pipeline, though it is far from commercialization.
+0.20Sionna Therapeutics has selected the SION-451 and SION-2222 pairing as its preferred dual-combination regimen moving forward. — Defining a path forward for remaining candidates creates a baseline for future development, though it is secondary to the main drug failure.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company discontinued a cystic fibrosis drug following unfavorable trial data, leading to a 91.84% stock price drop.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
16h ago
